POSTER PRESENTATION

Open Access

Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy

Mohan Karkada^{1*}, Mieko Ogura², Vivian Tovar², Masato Mitsuhashi², Neil Berinstein³, Marc Mansour¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Predicting the likelihood of a clinical outcome using biomarkers during the course of a cancer immunotherapy can be a powerful tool for time-sensitive decision making on personalized treatment options. In a clinical trial with the survivin-targeting vaccine DPX-Survivac, we showed using established methods (ELISpot/tetramer/flow cytometry) that a high-dose of DPX-Survivac vaccine in combination with low dose metronomic oral cyclophosphamide (mCPA) induced much stronger immune responses in ovarian cancer patients (cohort C, n=6) compared to vaccine alone (cohort A, n=6) or low dose vaccine with mCPA (cohort B, n=6). Immune responses were detected ex vivo in patients' PBMCs particularly in cohort C, a reflection of the magnitude of the immune responses generated by the vaccine. We further analyzed the kinetics of various T cell phenotypes of the CD4 and CD8 lineages, including effector/central memory T cells and late differentiated CD8 T cells. We established a model for the sequential appearance of polyfunctional T cells of the various phenotypes and for the persistence of these cell types following repeated immunizations with DPX-Survivac. In addition, we explored a unique PCR-based 'real-time' method developed by Hitachi Chemical Research Center for analyzing mRNA expression signatures that could be associated with vaccine induced immune responses. For this, small quantities of fresh blood from immunized patients were directly incubated with vaccine antigens and analyzed by qPCR at pre- and one month post-immunization time points. Among 9 immune response-related biomarkers tested, mRNA for molecules such as IFN- γ , GM-CSF, TNF- α and CXCL10 were detected de novo in the blood of four out of four subjects tested among six patients from cohort C at

one month following the third vaccination. These results are in keeping with the establishment of stronger immune responses and the kinetics of vaccine-induced memory/effector T cells observed at this time point in patients receiving the combination of DPX-Survivac and cyclophosphamide. Taken together, these findings provide a framework for identifying a potential immune response signature soon after initiation of the vaccine therapy. We will determine whether this immune response signature is predictive of clinical activity in a planned randomized phase 2 trial.

Authors' details

¹Immunovaccine Inc., Halifax, NS, Canada. ²Hitachi Chemical Research Center Inc., Irvine, CA, USA. ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P106

Cite this article as: Karkada et al.: Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P106.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

¹Immunovaccine Inc., Halifax, NS, Canada
Full list of author information is available at the end of the article